Research programme: cancer therapeutics - Endocyte
Alternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC-1744; EC1788; GARFTase inhibitors - EndocyteLatest Information Update: 28 Dec 2021
At a glance
- Originator Endocyte
- Class Depsipeptides; Doxorubicins; Drug conjugates; Folic acids; Oligopeptides; Small molecules; Taxanes
- Mechanism of Action Folate receptor 1 antagonists; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 21 Dec 2018 Endocyte has been acquired by Novartis